Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E R van Wering

Showing results (91-100 of 109) with videos related to

Pageof 11
Sort By:
British Journal of Cancer|December 8, 2005
The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemiaI Hubeek, R W Stam, G J Peters, et al.
Medical and Pediatric Oncology|May 2, 2002
In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study GroupsN L Ramakers-van Woerden, R Pieters, D Hoelzer, et al.
Leukemia|January 21, 2006
Incidence of additional genetic changes in the TEL and AML1 genes in DCOG and COALL-treated t(12;21)-positive pediatric ALL, and their relation with drug sensitivity and clinical outcomeW A G Stams, H B Beverloo, M L den Boer, et al.
Blood|July 27, 2000
TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemiaN L Ramakers-van Woerden, R Pieters, A H Loonen, et al.
Leukemia|March 23, 1999
Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALLP Lúcio, A Parreira, M W van den Beemd, et al.
British Journal of Haematology|March 22, 2001
In vitro drug resistance and prognostic impact of p16INK4A/P15INK4B deletions in childhood T-cell acute lymphoblastic leukaemiaN L Ramakers-van Woerden, R Pieters, R M Slater, et al.
Leukemia|January 9, 2004
In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotypeN L Ramakers-van Woerden, H B Beverloo, A J P Veerman, et al.
Leukemia|May 10, 2000
BIOMED-1 concerted action report: flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL)A Porwit-MacDonald, E Björklund, P Lucio, et al.
Leukemia|August 2, 2001
BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical EvaluationP Lucio, G Gaipa, E G van Lochem, et al.
Leukemia|August 19, 2005
Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trialsG Kardos, C M Zwaan, G J L Kaspers, et al.
Pageof 11

Showing results (91-100 of 109) with videos related to

Sort By:
Pageof 11
British Journal of Cancer|December 8, 2005
The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemiaI Hubeek, R W Stam, G J Peters, et al.
Medical and Pediatric Oncology|May 2, 2002
In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study GroupsN L Ramakers-van Woerden, R Pieters, D Hoelzer, et al.
Leukemia|January 21, 2006
Incidence of additional genetic changes in the TEL and AML1 genes in DCOG and COALL-treated t(12;21)-positive pediatric ALL, and their relation with drug sensitivity and clinical outcomeW A G Stams, H B Beverloo, M L den Boer, et al.
Blood|July 27, 2000
TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemiaN L Ramakers-van Woerden, R Pieters, A H Loonen, et al.
Leukemia|March 23, 1999
Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALLP Lúcio, A Parreira, M W van den Beemd, et al.
British Journal of Haematology|March 22, 2001
In vitro drug resistance and prognostic impact of p16INK4A/P15INK4B deletions in childhood T-cell acute lymphoblastic leukaemiaN L Ramakers-van Woerden, R Pieters, R M Slater, et al.
Leukemia|January 9, 2004
In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotypeN L Ramakers-van Woerden, H B Beverloo, A J P Veerman, et al.
Leukemia|May 10, 2000
BIOMED-1 concerted action report: flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL)A Porwit-MacDonald, E Björklund, P Lucio, et al.
Leukemia|August 2, 2001
BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical EvaluationP Lucio, G Gaipa, E G van Lochem, et al.
Leukemia|August 19, 2005
Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trialsG Kardos, C M Zwaan, G J L Kaspers, et al.
Pageof 11